Retatrutide Research Compound
$200.00
Retatrutide is a potential future medication known as a "Triple-G" agonist, targeting GLP-1, GIP, and Glucagon receptors. It is currently under investigation for obesity and diabetes.
Available: Research Vial (Various Strengths)
In Stock (50 available)
Why Choose N/A (Triple-G Agonist)?
As a novel triple agonist, Retatrutide represents the next generation in metabolic treatments, showing promising results in clinical trials for superior efficacy.
How to Use
For research purposes only. Not approved for human use. Follow strict laboratory protocols for handling and administration.
Safety Information
This product is for research use only. Not for human consumption. Handle with appropriate safety gear and procedures.
Potential Side Effects
Data from clinical trials suggests similar side effects to GLP-1 agonists (GI issues), but full profile is still emerging.
Product Facts
| Generic Name | Retatrutide |
| Brand Name | N/A (Triple-G Agonist) |
| Type of Medication | GLP-1, GIP, and Glucagon receptor agonist (Triple Agonist) |
| Indications | Investigational for obesity and Type 2 Diabetes. |
| Dosage Forms | Lyophilized powder for reconstitution/Injection |
| Administration | Once weekly |
| Special Precautions | Strictly for research use. Potential long-term effects are unknown. |
| Drug Interactions | Unknown due to investigational status. |
| Use in Specific Populations | Not applicable (Investigational) |
| Prescription | Not applicable (Research Use Only) |
| Manufacturer | Eli Lilly (In Trials) |
How to Buy
For accredited researchers and institutions only. Requires documented proof of research affiliation.